SQLite Web: event_store.db

Update row 22066 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-11T03:10:51.104915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:9884f8d95dc0d0be","evidence_event_ids":["evt_cfdcce08057e"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-151259.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-151259.txt","company":"Solid Biosciences Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-151259.txt","article_chars":3165,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_864c80b5c3bf6d3c","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-151259.txt","content_type":"text/plain","enriched_at":"2026-04-11T07:36:57.137895+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-151259.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-151259.txt","source_event_id":"evt_cfdcce08057e","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"7de4ccf9ca3ae2c4","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-10","2026 Annual Meeting of Stockholders","2027 Annual Meeting of Stockholders","2028 Annual Meeting of Stockholders"],"entities":[{"asset_class":"equity","name":"Solid Biosciences Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"person","name":"Ilan Ganot","relevance":"high","symbol":"","type":"person"},{"asset_class":"other","name":"Board of Directors of Solid Biosciences Inc.","relevance":"medium","symbol":"","type":"governance_body"}],"event_type":"other","information_gaps":["What the prior board composition was before the change (only the post-change counts are stated).","Whether any other directors/officers were affected (the text only describes Mr. Ganot\u2019s resignation/appointment).","No stock ticker/symbol for Solid Biosciences Inc. is provided in the provided text."],"key_facts":["Solid Biosciences Inc. filed a Form 8-K (Current Report).","Item 5.02 is included in the filing.","Effective at 4:00 p.m. Eastern Time on April 10, 2026, Ilan Ganot resigned from the Board while serving in Class III.","Effective simultaneously, the Board decreased the number of Class III directors to three, increased the number of Class I directors to three, and appointed Ilan Ganot to fill the vacancy in Class I.","Mr. Ganot\u2019s Class I term is stated as expiring at the Company\u2019s 2028 Annual Meeting of Stockholders.","The company states Mr. Ganot will not stand for re-election by stockholders at the Company\u2019s 2027 Annual Meeting because he moved from Class III to Class I.","The company will ask stockholders to ratify, on an advisory basis, the appointment of Mr. Ganot as a Class I Director at the Company\u2019s 2026 Annual Meeting of Stockholders.","The filing states there were no changes to Mr. Ganot\u2019s compensation arrangements and no compensation is due as a result of his resignation from Class III and appointment to Class I."],"numeric_claims":[{"label":"effective_time","value":"4:00 p.m. Eastern Time"},{"label":"effective_date","value":"April 10, 2026"},{"label":"classIII_directors_after","value":"3"},{"label":"classI_directors_after","value":"3"}],"primary_claim":"Effective April 10, 2026, Ilan Ganot resigned from the Board\u2019s Class III and was appointed to Class I, with the company planning an advisory stockholder ratification of his appointment at the 2026 Annual Meeting.","relevance_score":0.45,"sentiment":"neutral","source_quality":"high","summary":"Solid Biosciences Inc. filed a Form 8-K reporting a board change effective April 10, 2026: Ilan Ganot resigned from Class III and was appointed to fill a vacancy in Class I. The company will ask stockholders to ratify his Class I appointment on an advisory basis at the 2026 Annual Meeting.","topics":["SEC filing","8-K","board of directors","director resignation","director appointment","corporate governance","stockholder advisory ratification"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Solid Biosciences Inc. \u00b7 Filed 20260410","ticker":"SLDB","tickers":["SLDB"],"title":"SLDB filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-151259.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel